Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Revvity Inc. (RVTY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: RVTY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -40.89% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.71B USD | Price to earnings Ratio 46 | 1Y Target Price 141.1 |
Price to earnings Ratio 46 | 1Y Target Price 141.1 | ||
Volume (30-day avg) 989767 | Beta 1.07 | 52 Weeks Range 97.14 - 129.42 | Updated Date 04/1/2025 |
52 Weeks Range 97.14 - 129.42 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.26% | Basic EPS (TTM) 2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.81% | Operating Margin (TTM) 18.71% |
Management Effectiveness
Return on Assets (TTM) 1.97% | Return on Equity (TTM) 3.64% |
Valuation
Trailing PE 46 | Forward PE 21.37 | Enterprise Value 14873991858 | Price to Sales(TTM) 4.61 |
Enterprise Value 14873991858 | Price to Sales(TTM) 4.61 | ||
Enterprise Value to Revenue 5.4 | Enterprise Value to EBITDA 17.7 | Shares Outstanding 120147000 | Shares Floating 119570725 |
Shares Outstanding 120147000 | Shares Floating 119570725 | ||
Percent Insiders 0.33 | Percent Institutions 95.14 |
Analyst Ratings
Rating 4.05 | Target Price 137.14 | Buy 5 | Strong Buy 8 |
Buy 5 | Strong Buy 8 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Revvity Inc.
Company Overview
History and Background
Revvity Inc., formerly PerkinElmer, was founded in 1931. It initially focused on optical technology and diversified into life sciences, diagnostics, and environmental analysis. In 2023, PerkinElmer rebranded as Revvity to reflect its evolved focus on human health.
Core Business Areas
- Life Sciences and Diagnostics: Offers a range of instruments, reagents, software, and services for drug discovery, research, and diagnostics. Key products include imaging systems, detection technologies, and genomics solutions.
Leadership and Structure
Prahlad Singh serves as the CEO of Revvity. The company is structured with various business units focused on specific areas within life sciences and diagnostics.
Top Products and Market Share
Key Offerings
- BioLegend: Offers a wide range of antibodies, reagents, and kits for immunology research. Competitors include Thermo Fisher Scientific (TMO), BD Biosciences (BDX), and Miltenyi Biotec.
- Signals Image Artist: A cloud-based platform for scientific image analysis. Competitors include, but are not limited to, Indica Labs, Visiopharm, and Aiforia.
Market Dynamics
Industry Overview
The life sciences and diagnostics industry is experiencing growth driven by advancements in genomics, proteomics, and personalized medicine.
Positioning
Revvity holds a strong position in the market due to its diverse portfolio of products and services, as well as its focus on innovation and customer satisfaction.
Total Addressable Market (TAM)
The TAM for the life sciences and diagnostics market is substantial, estimated to be in the hundreds of billions of dollars. Revvity is positioned to capture a significant share of this market through its established presence and ongoing investments in research and development.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Established customer base
- Innovation capabilities
Weaknesses
- Dependence on acquisitions for growth
- Potential for integration challenges
- Exposure to regulatory changes
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Partnerships with pharmaceutical companies
- Increased adoption of personalized medicine
Threats
- Intense competition
- Pricing pressures
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILMN
- WAT
- AGIL
Competitive Landscape
Revvity faces intense competition from larger, more established players in the life sciences and diagnostics market. To compete effectively, Revvity needs to continue to innovate and focus on specific market segments where it can differentiate itself.
Major Acquisitions
BioLegend
- Year: 2021
- Acquisition Price (USD millions): 5250
- Strategic Rationale: Expanded Revvity's portfolio of antibodies and reagents for immunology research.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth trends are skewed with recent changes to Revvity. The figures cannot be used.
Future Projections: Future Projections are subject to current company direction. Please see financial analyst for projections.
Recent Initiatives: Recent Initiatives include the rebranding to Revvity and a strategic focus on life sciences and diagnostics.
Summary
Revvity is undergoing a transformation to focus on life sciences and diagnostics. It has a strong presence in its chosen segments but faces competition from larger players. The BioLegend acquisition significantly boosted its capabilities. The company must successfully execute its strategic initiatives and manage integration risks to achieve its growth objectives. Future projections are uncertain with the recent sale of the Applied, Food and Enterprise Services businesses.
Similar Companies
- TMO
- DHR
- ILMN
- WAT
- AGIL
- LH
- DGX
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revvity Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Mass
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.